For the quarter ended December 2025, Integra LifeSciences (IART) reported revenue of $434.93 million, down 1.7% over the same period last year. EPS came in at $0.83, compared to $0.97 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $434.35 million, representing a surprise of +0.13%. The company delivered an EPS surprise of +4.73%, with the consensus EPS estimate being $0.79.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...

Integra LifeSciences (NasdaqGS:IART) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris Ward - Senior Director of Investor RelationsLea Knight - EVP and CFOMojdeh Poul - President and CEOConference Call ParticipantsRavi Misra - Research AnalystNone - AnalystNone - AnalystNone - AnalystOperatorGood day, and welcome to the Integra LifeSciences fourth quarter 2025 financial results. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be ...

Integra LifeSciences (NasdaqGS:IART) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris Ward - Senior Director of Investor RelationsLea Knight - EVP and CFOMojdeh Poul - President and CEOConference Call ParticipantsRavi Misra - Research AnalystNone - AnalystNone - AnalystNone - AnalystOperatorGood day, and welcome to the Integra LifeSciences fourth quarter 2025 financial results. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be ...

Integra LifeSciences (NasdaqGS:IART) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker5Good day, and welcome to the Integra LifeSciences fourth quarter 2025 financial results. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question, please press star 1. To remove yourself from the queue, press star 1 1 again. This call may be recorded. I would now like to turn the call over to Chris Ward, Senior Director ...

Integra LifeSciences (IART) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.73%. A quarter ago, it was expected that this medical device maker would post earnings of $0.43 per share when it actually produced earnings of $0.54, delivering a surprise of +25.58%.Over the last four qua ...

EARNINGS PRESENTATION Q4 2025 February 26, 2026 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may ...

News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance Princeton, New Jersey, February 26, 2026 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Full-Year 2025 "In the fourth quarter, we drove tangible operational progress while continuing to deliver for our customers and patients," said Mojdeh Poul, president ...

PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share ...

Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, representing decades of experience in the MedTech industryPRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief ...

PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those ...